Skip to main content
. 2019 Jun 21;27(6):635–641. doi: 10.3727/096504018X15288447760357

Table 2.

Clinical Activity of Apatinib Plus Systemic Chemotherapy

Patient No. %
Complete response 0 0
Partial response 6 30%
Stable disease 10 50%
Progressive disease 4 20%
Objective response rate 30%
Median progression-free survival 3.0 months
Disease control rate 80%